Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer

Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and... RESEARCH ARTICLE Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer Hemangini H. Vora, PhD,* Nupur A. Patel, MSc,* Prushin M. Thakore, MPharm, and Shilin N. Shukla, MDw n India, breast cancer has been declared the most Aim: This study evaluated wild-type EGFR, E746-A750 frame Icommon form of cancer in women, almost surpassing deletion in exon 19, and L858R point mutation in exon 21 by cervical cancer. A recent study of breast cancer risk in immunohistochemistry in patients with triple-negative breast India revealed that 1 in 28 women develops breast cancer cancer (TNBC). during her lifetime. This is higher in urban areas being 1 in 22 in a lifetime due to change in lifestyle factors com- Methods: A retrospective study included 99 untreated early- pared with rural areas where this risk is relatively much stage and advanced-stage TNBC patients. Immuno- lower being 1 in 60 women developing breast cancer in histochemical localization of wild-type EGFR, EGFR E746- their lifetime. A750 deletion in exon 19, and EGFR L858R mutation in exon Because of disease heterogeneity, molecular classi- 21 was performed on formalin-fixed paraffin-embedded tissue fication has become http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer

Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Mar 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/immunohistochemical-localization-of-wild-type-egfr-e746-a750-frame-cuhbCEHl6Q
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000127
pmid
25789532
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer Hemangini H. Vora, PhD,* Nupur A. Patel, MSc,* Prushin M. Thakore, MPharm, and Shilin N. Shukla, MDw n India, breast cancer has been declared the most Aim: This study evaluated wild-type EGFR, E746-A750 frame Icommon form of cancer in women, almost surpassing deletion in exon 19, and L858R point mutation in exon 21 by cervical cancer. A recent study of breast cancer risk in immunohistochemistry in patients with triple-negative breast India revealed that 1 in 28 women develops breast cancer cancer (TNBC). during her lifetime. This is higher in urban areas being 1 in 22 in a lifetime due to change in lifestyle factors com- Methods: A retrospective study included 99 untreated early- pared with rural areas where this risk is relatively much stage and advanced-stage TNBC patients. Immuno- lower being 1 in 60 women developing breast cancer in histochemical localization of wild-type EGFR, EGFR E746- their lifetime. A750 deletion in exon 19, and EGFR L858R mutation in exon Because of disease heterogeneity, molecular classi- 21 was performed on formalin-fixed paraffin-embedded tissue fication has become

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2015

There are no references for this article.